Download PDF
Dialyse aktuell 2015; 19(2): 96-103
DOI: 10.1055/s-0035-1549269
Nephrologie
© Georg Thieme Verlag Stuttgart · New York

Zitratantikoagulation – Hintergründe zur Behandlung von Nierenkranken

Citrate anticoagulation – Background knowledge regarding therapy of patients with renal failure
Christian Aymanns
1   Bereich Nephrologie, Dialyse und Hochdruckkrankheiten, Klinik für Innere Medizin A, Universitätsmedizin Greifswald (Bereichsleitung: Prof. Dr. Sylvia Stracke)
› Author Affiliations
Further Information

Publication History

Publication Date:
26 March 2015 (online)

Also available at
    Permissions and Reprints

Patienten mit akutem oder chronischem Nierenversagen weisen gegenüber Nierengesunden ein erhöhtes Blutungsrisiko auf. Soll eine Nierenersatzbehandlung erfolgen, wird das Blutungsrisiko durch Heparin nochmals gesteigert. Liegen bereits Blutungen vor oder ist das Blutungsrisiko sehr hoch, liegt es nahe, auf Heparin nach Möglichkeit zu verzichten. Bereits in den 1960er-Jahren wurde das erste Mal über die regionale Antikoagulation mit Zitrat zur Aufrechterhaltung eines extrakorporalen Kreislaufs geschrieben. Diese Form der Antikoagulation hat sich in den letzten Jahren vor allem im intensivmedizinischen Bereich etabliert. Aber auch die intermittierende Hämodialyse kann mit gutem Erfolg langfristig mit Zitrat durchgeführt werden. Die technische Umsetzung wird von den kommerziellen Anbietern zunehmend besser gelöst und vereinfacht. Trotzdem sind intensive Personalschulungen insbesondere bei der Einführung der regionalen Zitratantikoagulation notwendig, um für die möglichen Komplikationen und deren Behandlung zu sensibilisieren. In erster Linie sind Störungen im Kalzium- und Säure-Basen-Haushalt zu erwarten. Diese sind bei adäquater Umsetzung der Behandlungsprotokolle aber selten und behandelbar.

Patients with acute or chronic renal failure have a higher bleeding risk compared to patients with normal renal function. Administration of heparin during renal replacement therapy even more increases the risk. Thus, in patients with actual bleeding or very high bleeding risk it should be considered to avoid heparin. Regional citrate anticoagulation for renal replacement therapy, first described in 1961, has evolved into a standard procedure in the last years, especially for continuous renal replacement therapy in intensive care units. Although serious complications are rare, personnel training is needed, especially during implementation phase. The most common complications are disturbances of calcium and acid-base balance which can be detected and managed reliably when treatment protocols are followed.

Key words

regional citrate anticoagulation - renal replacement therapy - haemodialysis
 

  • Literatur

  • 1 Huang KW, Leu HB, Luo JC et al. Different peptic ulcer bleeding risk in chronic kidney disease and end-stage renal disease patients receiving different dialysis. Dig Dis Sci 2014; 59: 807-813
    CrossrefGoogle Scholar
  • 2 Acedillo RR, Shah M, Devereaux PJ et al. The risk of perioperative bleeding in patients with chronic kidney disease: a systematic review and meta-analysis. Ann Surg 2013; 258: 901-913
    CrossrefPubMedGoogle Scholar
  • 3 Oudemans-van Straaten HM, Wester JPJ, de Pont AC, Schetz MR. Anticoagulation strategies in continuous renal replacement therapy: can the choice be evidence based?. Intensive Care Med 2006; 32: 188-202
    CrossrefGoogle Scholar
  • 4 Morita Y, Johnson RW, Dorn RE, Hall DS. Regional anticoagulation during hemodialysis using citrate. Am J Med Sci 1961; 242: 32-43
    CrossrefGoogle Scholar
  • 5 Seaton RD, Duncan KA, Pinnick RV et al. Regional citrate anticoagulation in chronic hemodialysis patients. Trans Am Soc Artif Intern Organs 1983; 29: 414-418
    Google Scholar
  • 6 Pinnick RV, Wiegmann TB, Diederich DA. Regional citrate anticoagulation for hemodialysis in the patient at high risk for bleeding. N Engl J Med 1983; 308: 258-261
    CrossrefGoogle Scholar
  • 7 Kidney Disease: Improving Global Outcomes (KDIGO) Acute Kidney Injury Work Group. KDIGO Clinical Practice Guideline for Acute Kidney Injury. Kidney Int Suppl 2012; 2: 1-138
    CrossrefGoogle Scholar
  • 8 Oudemans-van Straaten HM, Ostermann M. Bench-to-bedside review: citrate for continuous renal replacement therapy, from science to practice. Crit Care 2012; 16: 249-249
    CrossrefGoogle Scholar
  • 9 Mariano F, Morselli M, Bergamo D et al. Blood and ultrafiltrate dosage of citrate as a useful and routine tool during continuous venovenous haemodiafiltration in septic shock patients. Nephrol Dial Transplant 2011; 26: 3882-3888
    CrossrefGoogle Scholar
  • 10 Zhang Z, Hongying N. Efficacy and safety of regional citrate anticoagulation in critically ill patients undergoing continuous renal replacement therapy. Intensive Care Med 2012; 38: 20-28
    CrossrefGoogle Scholar
  • 11 Wu MY, Hsu YH, Bai CH et al. Regional citrate versus heparin anticoagulation for continuous renal replacement therapy: a meta-analysis of randomized controlled trials. Am J Kidney Dis 2012; 59: 810-818
    CrossrefGoogle Scholar
  • 12 Monchi M, Berghmans D, Ledoux D et al. Citrate vs. heparin for anticoagulation in continuous venovenous hemofiltration: a prospective randomized study. Intensive Care Med 2004; 30: 260-265
    CrossrefGoogle Scholar
  • 13 Morabito S, Pistolesi V, Tritapepe L et al. Regional citrate anticoagulation in cardiac surgery patients at high risk of bleeding: a continuous veno-venous hemofiltration protocol with a low concentration citrate solution. Crit Care 2012; 16
    Google Scholar
  • 14 Hetzel GR, Schmitz M, Wissing H et al. Regional citrate versus systemic heparin for anticoagulation in critically ill patients on continuous venovenous haemofiltration: a prospective randomized multicentre trial. Nephrol Dial Transplant 2011; 26: 232-239
    CrossrefGoogle Scholar
  • 15 Schilder L, Nurmohamed SA, Bosch FH et al. CASH study group. Citrate anticoagulation versus systemic heparinisation in continuous venovenous hemofiltration in critically ill patients with acute kidney injury: a multi-center randomized clinical trial. Crit Care 2014; 18: 472-472
    CrossrefGoogle Scholar
  • 16 Oudemans-van Straaten HM, Bosman RJ, Koopmans M et al. Citrate anticoagulation for continuous venovenous hemofiltration. Crit Care Med 2009; 37: 545-552
    CrossrefGoogle Scholar
  • 17 Schilder L, Nurmohamed SA, ter Wee PM et al. Citrate confers less filter-induced complement activation and neutrophil degranulation than heparin when used for anticoagulation during continuous venovenous haemofiltration in critically ill patients. BMC Nephrol 2014; 15: 19-19
    CrossrefGoogle Scholar
  • 18 Morabito S, Pistolesi V, Tritapepe L, Fiaccadori E. Regional Citrate Anticoagulation for RRTs in Critically Ill Patients with AKI. Clin J Am Soc Nephrol 2014; 9: 2173-2188
    CrossrefGoogle Scholar
  • 19 Joannidis M, Oudemans-van Straaten HM. Clinical review: patency of the circuit in continuous renal replacement therapy. Crit Care 2007; 11: 218-218
    CrossrefGoogle Scholar
  • 20 Gubenšek J, Kovač J, Benedik M et al. Long-term citrate anticoagulation in chronic hemodialysis patients. Ther Apher Dial 2011; 15: 278-282
    CrossrefGoogle Scholar
  • 21 Szamosfalvi B, Frinak S, Yee J. Sensors and hybrid therapies: a new approach with automated citrate anticoagulation. Blood Purif 2012; 34: 80-87
    CrossrefGoogle Scholar
  • 22 Hetzel GR, Taskaya G, Sucker C et al. Citrate plasma levels in patients under regional anticoagulation in continuous venovenous hemofiltration. Am J Kidney Dis 2006; 48: 806-811
    CrossrefGoogle Scholar
  • 23 Kramer L, Bauer E, Joukhadar C et al. Citrate pharmacokinetics and metabolism in cirrhotic and noncirrhotic critically ill patients. Crit Care Med 2003; 31: 2450-2455
    CrossrefGoogle Scholar
  • 24 Khadzhynov D, Schelter C, Lieker I et al. Incidence and outcome of metabolic disarrangements consistent with citrate accumulation in critically ill patients undergoing continuous venovenous hemodialysis with regional citrate anticoagulation. J Crit Care 2014; 29: 265-271
    CrossrefGoogle Scholar
  • 25 Schultheiß C, Saugel B, Phillip V et al. Continuous venovenous hemodialysis with regional citrate anticoagulation in patients with liver failure: a prospective observational study. Crit Care 2012; 16
    Google Scholar
  • 26 Klingele M, Seiler S, Poppleton A et al. The gap between calculated and actual calcium substitution during citrate anticoagulation in an immobilised patient on renal replacement therapy reflects the extent of bone loss - a case report. BMC Nephrol 2014; 15: 163-163
    CrossrefGoogle Scholar
  • 27 Fall P, Szerlip HM. Continuous renal replacement therapy: cause and treatment of electrolyte complications. Semin Dial 2010; 23: 581-585
    CrossrefGoogle Scholar
  • 28 Wright S, Steinwandel U, Ferrari P. Citrate anticoagulation using ACD solution A during long-term haemodialysis. Nephrology (Carlton) 2011; 16: 396-402
    CrossrefGoogle Scholar